Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. (Nasdaq: CELC), an emerging growth company incorporated in Delaware, on June 5, 2020. The report details the entry into a material definitive agreement regarding the potential sale of common stock.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization to raise up to $10,000,000 in aggregate offering price through an At Market Issuance Sales Agreement.
Material Changes
On June 5, 2020, the Company entered into a Sales Agreement with B. Riley FBR, Inc. as the agent. This agreement allows Celcuity to offer and sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $10,000,000. The sales will be conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-227466) and a prospectus supplement dated June 5, 2020.
Guidance, Outlook, and Terms
- Sales Method: Shares may be sold through "at the market offerings" as defined in Rule 415 of the Securities Act, including ordinary brokers' transactions on The Nasdaq Capital Market.
- Commission: The Company will pay B. Riley FBR a commission equal to 3.0% of the aggregate gross proceeds from each sale of shares.
- Expenses: The Company agreed to reimburse B. Riley FBR for certain specified expenses related to the agreement.
- Termination: The offering will terminate upon the sale of all shares or the termination of the agreement by either party.
- Obligation: The Company is not obligated to make any sales of shares under this agreement.
Investor Verification Checklist
- Verify the current market price of CELC common stock to assess potential dilution from the $10,000,000 offering.
- Review the full text of the At Market Issuance Sales Agreement (Exhibit 1.1) for specific conditions and termination rights.
- Confirm the status of the shelf registration statement (File No. 333-227466) and the prospectus supplement.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.